Probar la medicina

La mayoría de la gente se sorprende cuando se entera de que la aplicación rigurosa de reglas formales de evidencia para evaluar la investigación médica y decidir cuáles son los mejores tratamientos es un fenómeno reciente. Tal vez se sorprendería de la misma manera si supiera que la política sanitaria aún no es objeto del mismo tratamiento.

La llamada "medicina basada en la evidencia" implica una jerarquía de pruebas empíricas que califica a los estudios médicos según su calidad. La investigación fisiológica en animales o de respuestas humanas en el laboratorio califican bajo en la jerarquía. Los estudios de observación que comparan resultados para pacientes que reciben determinados tratamientos y controlan a otros que no califican mejor, pero aún así pueden ser engañosos.

Los estudios convincentes de drogas y procedimientos quirúrgicos por lo general sólo surgen de pruebas aleatorias, en las que los pacientes reciben tratamiento o no en base a un proceso comparable a tirar una moneda al aire. Las pruebas aleatorias bien realizadas incorporan salvaguardas adicionales contra el prejuicio, como ser el uso de placebos que les permitan a los investigadores ocultarles a pacientes y profesionales de la salud si los pacientes están recibiendo o no un tratamiento activo.

To continue reading, please log in or enter your email address.

Registration is quick and easy and requires only your email address. If you already have an account with us, please log in. Or subscribe now for unlimited access.

required

Log in

http://prosyn.org/C51grVa/es;
  1. An employee works at a chemical fiber weaving company VCG/Getty Images

    China in the Lead?

    For four decades, China has achieved unprecedented economic growth under a centralized, authoritarian political system, far outpacing growth in the Western liberal democracies. So, is Chinese President Xi Jinping right to double down on authoritarianism, and is the “China model” truly a viable rival to Western-style democratic capitalism?

  2. The assembly line at Ford Bill Pugliano/Getty Images

    Whither the Multilateral Trading System?

    The global economy today is dominated by three major players – China, the EU, and the US – with roughly equal trading volumes and limited incentive to fight for the rules-based global trading system. With cooperation unlikely, the world should prepare itself for the erosion of the World Trade Organization.

  3. Donald Trump Saul Loeb/Getty Images

    The Globalization of Our Discontent

    Globalization, which was supposed to benefit developed and developing countries alike, is now reviled almost everywhere, as the political backlash in Europe and the US has shown. The challenge is to minimize the risk that the backlash will intensify, and that starts by understanding – and avoiding – past mistakes.

  4. A general view of the Corn Market in the City of Manchester Christopher Furlong/Getty Images

    A Better British Story

    Despite all of the doom and gloom over the United Kingdom's impending withdrawal from the European Union, key manufacturing indicators are at their highest levels in four years, and the mood for investment may be improving. While parts of the UK are certainly weakening economically, others may finally be overcoming longstanding challenges.

  5. UK supermarket Waring Abbott/Getty Images

    The UK’s Multilateral Trade Future

    With Brexit looming, the UK has no choice but to redesign its future trading relationships. As a major producer of sophisticated components, its long-term trade strategy should focus on gaining deep and unfettered access to integrated cross-border supply chains – and that means adopting a multilateral approach.

  6. The Year Ahead 2018

    The world’s leading thinkers and policymakers examine what’s come apart in the past year, and anticipate what will define the year ahead.

    Order now